Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine
Amount Raised
$230 Million
Round Type
Series B
SomervilleSoftwareHealth CareScience And EngineeringDescription
Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing. The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2i, with participation from Qatar Investment Authority (QIA) and others.
Quick answer
Tessera Therapeutics raised $230 Million in a Series B round, dated January 12, 2021. Tessera Therapeutics is based in Somerville, Massachusetts, United States.
- How much did Tessera Therapeutics raise?
- Tessera Therapeutics raised $230 Million in a Series B round on January 12, 2021.
- What does Tessera Therapeutics do?
- Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome,..
- Where is Tessera Therapeutics based and how big is it?
- Tessera Therapeutics is based in Somerville, Massachusetts, United States.
- Who are the decision-makers at Tessera Therapeutics?
- Fundz holds 1 contact at Tessera Therapeutics, including the Chief Human Resources Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Software around the same time
Companies in the same sectors as Tessera Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- BetterUp raised $147M on February 26, 2021.
- Highspot raised $201M on February 25, 2021.
- SentinelOne, Inc. raised $103M on February 24, 2021.
- Enveric Biosciences raised an undisclosed amount on February 24, 2021.
- OpenLoop raised $1.3M (Seed) on February 23, 2021.
- Viome raised $3M (Seed) on February 11, 2021.
Who to call at Tessera Therapeutics, and when
A new round usually means Tessera Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Tessera Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tessera Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tessera Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tessera Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTessera Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.